AMPE

Ampio Pharmaceuticals, Inc
AMPE
Market cap $13.2M

Delisted

AMPE was delisted on the 3rd of October, 2022.

Back to rankings

About: Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Its lead product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress.

Employees: 18

Healthcare Drug Manufacturers - General

Financial journalist opinion

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern.

Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation

Ampio Announces Voluntary Delisting and SEC Deregistration

ENGLEWOOD, Colo. , March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Provides Update on Results from Pre-IND Enabling Studies

ENGLEWOOD, Colo. , Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.

Ampio Provides Update on Results from Pre-IND Enabling Studies

Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions

ENGLEWOOD, Colo. , Jan. 11, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has reached settlements in principle in the pending securities fraud class action, Case Number 22-cv-2105-WJM-MEH (the "Securities Class Action"), and the pending consolidated derivative actions in the United States District Court for the District of Colorado, Case Number 22-cv-2803-KLM (the "Consolidated Derivative Actions").

Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions

See News Rankings

Charts implemented using Lightweight Charts™